Dual-Targeting Mn@CeO2 Nanozyme-Modified Probiotic Hydrogel Microspheres Reshape Gut Homeostasis in Inflammatory

Pinwen Zhou1, Qi Sun2, Longchang Huang1

  • 1Clinical Nutrition Service Center, Department of General Surgery, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.

ACS Nano
|August 25, 2025
PubMed

Insights

This study developed nanozyme-coated probiotics encapsulated in alginate microspheres for improved inflammatory bowel disease (IBD) treatment. The novel delivery system enhances probiotic efficacy and targets inflamed gut regions, offering a promising therapeutic strategy.

Area of Science:

  • Biomedical Engineering
  • Microbiology
  • Materials Science

Background:

  • Oral probiotics show promise for inflammatory bowel disease (IBD) but face delivery challenges.
  • Existing probiotics struggle with gastrointestinal survival, antioxidant stability, and targeted delivery to inflamed gut tissues.

Purpose of the Study:

  • To develop an advanced probiotic delivery system for enhanced IBD treatment.
  • To improve probiotic survival, targeted delivery, and therapeutic efficacy using nanozyme coating and alginate microspheres.

Main Methods:

  • Synthesized Mn@CeO2 nanozymes to scavenge reactive oxygen species (ROS).
  • Coated Limosilactobacillus reuteri with nanozymes and encapsulated them in sodium alginate microspheres (MnCe@LR/AMs) via electrostatic spray.
  • Evaluated MnCe@LR/AMs in a mouse model of colitis.

Main Results:

  • MnCe@LR/AMs demonstrated enhanced ROS scavenging and stability in acidic environments.
  • The system exhibited dual-targeting to inflamed sites via mannose receptor binding.
  • Treatment with MnCe@LR/AMs improved intestinal barrier function, microbial diversity, and probiotic abundance.
  • Therapeutic effects included synergistic antioxidant/anti-inflammatory activities, enhanced amino acid absorption, and modulated macrophage polarization.

Conclusions:

  • MnCe@LR/AMs represent a promising strategy for advanced IBD therapy.
  • The nanozyme-alginate microsphere system significantly improves probiotic delivery precision and efficacy.
  • This approach offers a novel platform for developing targeted microbiome-based therapies for IBD.

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
189
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
382
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
267
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
595
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
331